Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Breast Neoplasms 558Carcinoma, Non-Small-Cell Lung 517Prostatic Neoplasms 335Colorectal Neoplasms 273Neoplasms 268Multiple Myeloma 267Leukemia, Myeloid, Acute 224Squamous Cell Carcinoma of Head and Neck 217Lung Neoplasms 210Neoplasm Metastasis 205Carcinoma, Hepatocellular 197Melanoma 175Triple Negative Breast Neoplasms 173Pancreatic Neoplasms 171Recurrence 152Ovarian Neoplasms 152Lymphoma 141Glioblastoma 134Brain Neoplasms 133Sarcoma 130Carcinoma, Renal Cell 129Stomach Neoplasms 125Lymphoma, Large B-Cell, Diffuse 125Leukemia, Lymphocytic, Chronic, B-Cell 125Head and Neck Neoplasms 125Rectal Neoplasms 109Precursor Cell Lymphoblastic Leukemia-Lymphoma 109Myelodysplastic Syndromes 103Uterine Cervical Neoplasms 100Urinary Bladder Neoplasms 100

Interventions

Sodium Chloride 1BNT162 Vaccine 12019-nCoV Vaccine mRNA-1273 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Severe Acute Respiratory Syndrome × 1 year × Clear all
NCT04761822 2025-08-12

SARS

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Completed
746 enrolled 28 charts
Myeloid

COVID-19, Hypersensitivity, Mastocytosis, Severe Acute Respiratory Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡